Galectin Therapeutics
GALT
49 hedge funds and large institutions have $12.5M invested in Galectin Therapeutics in 2017 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 16 reducing their positions, and 7 closing their positions.
51% more capital invested
Capital invested by funds: $8.3M → $12.5M (+$4.21M)
14% more call options, than puts
Call options by funds: $1.34M | Put options by funds: $1.18M
0% more funds holding
Funds holding: 49 → 49 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
0.61% less ownership
Funds ownership: 11.1% → 10.49% (-0.61%)
56% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$162K |
| 2 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$129K |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$116K |
| 4 |
ARTA
A.R.T. Advisors
New York
|
+$91.2K |
| 5 |
WS
Wedbush Securities
Los Angeles,
California
|
+$77.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$249K |
| 2 |
Morgan Stanley
New York
|
-$221K |
| 3 |
CCM
Courage Capital Management
Nashville,
Tennessee
|
-$202K |
| 4 |
BSW
Buckingham Strategic Wealth
Clayton,
Missouri
|
-$101K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$59.9K |
GALT Hedge Fund Activity: Q4 2017 in Review
49 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q4 2017, worth a combined $12.5M — up 51% from $8.3M a quarter earlier.
Fund positioning in GALT was balanced in Q4 2017: 7 funds opened new positions, 7 closed out, 7 added to existing stakes and 16 trimmed.
The largest buyer was Vanguard Group, adding an estimated $162K. The largest seller was Susquehanna International Group, cutting an estimated $249K.
- 49 institutional investors held Galectin Therapeutics (GALT) as of Q4 2017, unchanged from Q3 2017.
- Funds reported $12.5M of Galectin Therapeutics stock for Q4 2017, up 51% quarter-over-quarter.
- 7 funds opened new Galectin Therapeutics positions in Q4 2017 and 7 closed out, a net change of 0 holders.
- The largest Galectin Therapeutics buyer in Q4 2017 was Vanguard Group, an estimated $162K added.
- The largest Galectin Therapeutics seller in Q4 2017 was Susquehanna International Group, an estimated $249K sold.
Based on aggregated 13F filings for Q4 2017.